Joseph Caveney, MD
Medical Oncology · Morgantown, WVNPI 1609211614
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.1% of the total across 59 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $779 and has fallen 58.9% since, to $320 in 2025.
Across 59 payments — averaging $32.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$303
- Astellas Pharma US Inc$228
- Bristol Myers Squibb$208
- Seagen Inc.$186
- Jazz Pharmaceuticals Inc.$123
- Takeda Pharmaceuticals U.S.A., Inc.$123
- plus $721 from 12 others
What the payments were for
- Food & beverage$1,70590%
- Education$18710%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 4 | $303 |
| Astellas Pharma US Inc | 7 | $228 |
| Bristol Myers Squibb | 6 | $208 |
| Seagen Inc. | 4 | $186 |
| Jazz Pharmaceuticals Inc. | 4 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $123 |
| Pfizer | 4 | $99 |
| Novartis | 5 | $95 |
| AbbVie | 3 | $86 |
| Servier Pharmaceuticals LLC | 4 | $85 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| Genmab U.S., Inc. | 2 | $60 |
| Gilead | 3 | $59 |
| Johnson & Johnson | 2 | $53 |
| Daiichi Sankyo Inc. | 2 | $51 |
| Adaptive Biotechnologies Corporation | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few medical oncology providers in West Virginiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 24 | $189 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 24 | $99 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Morgantown
- Richard GoldbergMorgantown$66K
- Darrell SaundersMorgantown$282
- Aneel ChowdharyHuntington$420K
- Gerrit KimmeyHuntington$13K
- Waris WarisLogan$10K
- Rajiv KhannaBeckley$8K
- Mayez El HarakeBeckley$5K
- Juan Castro-GonzalezCharleston$2K
- William HarlessCharleston$481
- Justin CohenCharleston$418
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.